Cory M Johannessen

Cory M Johannessen

UNVERIFIED PROFILE

Are you Cory M Johannessen?   Register this Author

Register author
Cory M Johannessen

Cory M Johannessen

Publications by authors named "Cory M Johannessen"

Are you Cory M Johannessen?   Register this Author

29Publications

1038Reads

13Profile Views

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

Cancer Cell 2019 Oct 19;36(4):369-384.e13. Epub 2019 Sep 19.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building, Room DA-520, Boston MA 02215-02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.08.005DOI Listing
October 2019

A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.

Cancer Res 2019 May 28;79(9):2352-2366. Epub 2019 Feb 28.

Cancer Program, The Broad Institute of M.I.T. and Harvard, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-2711DOI Listing
May 2019

A Convergence-Based Framework for Cancer Drug Resistance.

Cancer Cell 2018 05;33(5):801-815

Eli Lilly and Company, Indianapolis, IN 46225, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.03.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957297PMC
May 2018

Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery.

Trends Genet 2015 Jan 12;31(1):16-23. Epub 2014 Dec 12.

Center for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tig.2014.11.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281276PMC
January 2015

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

Cancer Discov 2014 Jan 21;4(1):94-109. Epub 2013 Nov 21.

1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School; 2Department of Pathology, Massachusetts General Hospital Cancer Center, Boston; 3Broad Institute of MIT and Harvard; 4Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts; 5Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen; 6German Cancer Consortium (DKTK); 7Department of Dermatology, Heidelberg University Hospital, Heidelberg; 8Department of Dermatology and Allergy, Hannover Medical School, Hannover; 9Department of Dermatology, University of Wuerzburg, Wuerzburg; 10Department of Dermatology, Venerology and Allergology, University of Schleswig-Holstein Hospital, Kiel; 11Department of Dermatology and Allergology, Ludwig-Maximilian University, Munich; 12Department of Dermatology, Venerology and Allergy, Charité Universitätsmedizin Berlin, Humboldt University, Berlin; 13Department of Dermatology, University of Mainz, Mainz; 14University Medical Center, University of Tübingen, Tübingen, Germany; 15Department of Genome Sciences, University of Washington, Seattle, Washington; 16Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; and 17First Department of Medicine, Medical School, University of Athens, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0617DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947264PMC
January 2014

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

Cancer Discov 2014 Jan 21;4(1):61-8. Epub 2013 Nov 21.

1Department of Medical Oncology, Dana-Farber Cancer Institute; 2Department of Medicine, Brigham and Women's Hospital; 3Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; 4Broad Institute of Harvard and MIT; and 5Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0631DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947296PMC
January 2014

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.

Nature 2013 Dec 3;504(7478):138-42. Epub 2013 Nov 3.

1] The Broad Institute of Harvard University and Massachusetts Institute of Technology, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA [2] Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA [3] Harvard Medical School, 25 Shattuck Street, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature12688DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4098832PMC
December 2013

TORC1 is essential for NF1-associated malignancies.

Curr Biol 2008 Jan 27;18(1):56-62. Epub 2007 Dec 27.

Genetics Division, Department of Medicine, Brigham and Women's Hospital, Ludwig Center at Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cub.2007.11.066DOI Listing
January 2008

A negative feedback signaling network underlies oncogene-induced senescence.

Cancer Cell 2006 Dec;10(6):459-72

Genetics Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 458c NRB, 77 Louis Pasteur Avenue, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2006.10.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692661PMC
December 2006

Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma.

Cancer Res 2006 Oct;66(19):9362-8

Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-1619DOI Listing
October 2006

Regulation of mTOR and cell growth in response to energy stress by REDD1.

Mol Cell Biol 2005 Jul;25(14):5834-45

Massachusetts General Hospital Cancer Center and Harvard Medical School, GRJ-904, 55 Fruit Street, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.25.14.5834-5845.2005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168803PMC
July 2005

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

Proc Natl Acad Sci U S A 2005 Jun 3;102(24):8573-8. Epub 2005 Jun 3.

Genetics Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 458c NRB, 77 Louis Pasteur Avenue, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0503224102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1142482PMC
June 2005

REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species.

Mol Cell 2002 Nov;10(5):995-1005

Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1097-2765(02)00706-2DOI Listing
November 2002